Slide 1: ImageneBio Corporate Overview
ImageneBio Corporate Overview August 2026
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This investor presentation and any accompanying oral commentary have been prepared by ImageneBio, Inc. (the Company) for informational purposes only and not for any other purpose. This investor presentation and any accompanying oral commentary contain "forwa
Slide 3: Innovating in immunology
Innovating in immunology Established as a public company (NASDAQ: Anchored on olevaprubart (oleva, formerly IMG- IMA) in July 2025 through Inmagene-Ikena 007), a differentiated anti-OX40 monoclonal reverse merger and concurrent financing antibody (mAb) in phase 2b for atopic dermatitis (AD), the mos
Slide 4: Olevaprubart: Next generation anti-OX40 mAb with pipeline in a product potential
Olevaprubart: Next generation anti-OX40 mAb with pipeline in a product potential Proof of concept Confirmatory development Topline data Atopic Dermatitis expected in Phase 1b/2a Phase 2b Q4 2027 Oleva Alopecia Areata Initiating in 2026; Initial Phase 1b/2a Phase 2 data expected in 2028 Advancing Pha
Slide 5: OX40 signaling plays a central role in inflammation, with involvement across multiple T cell subtypes
OX40 signaling plays a central role in inflammation, with involvement across multiple T cell subtypes • OX40 is a receptor protein that is highly expressed on various subtypes of activated T cells • Upregulated OX40 expression has been found in the circulation, skin, and scalp of patients with atopi
Slide 6: Designed to be different: Olevaprubart, a next generation anti-OX40 mAb
Designed to be different: Olevaprubart, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Oleva has a trifecta of 2. T cell-preserving for safety and tolerability differentiating features 3. Extended half-life for patient- and physician-friendly dosing schedules 6
Slide 7: Designed to be different: Olevaprubart, a next generation anti-OX40 mAb
Designed to be different: Olevaprubart, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Targeting OX40 receptor (OX40) rather than OX40 ligand (OX40L) allows oleva to inhibit OX40-OX40L signaling in both blood and tissues. 2. T cell-preserving for safety and tolera
Slide 8: Designed to be different: Olevaprubart, a next generation anti-OX40 mAb
Designed to be different: Olevaprubart, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Illustrative OX40/OX40L Interaction Targeting OX40 receptor (OX40) rather than OX40 ligand (OX40L) allows oleva to inhibit OX40-OX40L signaling in both blood and tissues. 2. T c
Slide 9: Designed to be different: Olevaprubart, a next generation anti-OX40 mAb
Designed to be different: Olevaprubart, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Half-Life Targeting OX40 receptor (OX40) rather than OX40 ligand (OX40L) allows oleva to inhibit OX40-OX40L signaling in both blood and tissues. Roca 2. T cell-preserving for sa
Slide 10: Atopic dermatitis is a large and growing disease area where true innovation could have tremendous impact
Atopic dermatitis is a large and growing disease area where true innovation could have tremendous impact LARGE, GROWING MARKET…WITH 49M $16B ~15% ~40% Moderate-to-severe Global revenues in Eligible patients receive Report inadequate disease HEADROOM patients with AD globally1 2026 with ~10% advanced
Slide 11: OX40's role across T cell subsets underscores its potential in atopic dermatitis
OX40’s role across T cell subsets underscores its potential in atopic dermatitis • Atopic dermatitis is immunologically heterogeneous, with several pathogenic inflammatory pathways often activated at once; • Inhibiting the OX40/OX40L signaling cascade is a promising therapeutic strategy because it c
Slide 12: First generation OX40 antagonists illustrated the potential for deep responses
First generation OX40-OX40 antagonists illustrated the potential for patients to achieve impressively deep responses What could be possible with olevaprubart, a next generation anti OX40 antibody? vIGA-0/1 EASI-90 Proportion of patients achieving vIGA-0/1 57.4 60.2 % Responders Week In February 2026
Slide 13: Olevaprubart Phase 1b/2a in adults with moderate-to-severe atopic dermatitis enrolled a typical patient population
Olevaprubart Phase 1b/2a in adults with moderate-to-severe atopic dermatitis (AD) enrolled a typical patient population Patient demographics, n=13 Mean Age, years (SD): 49.8 (15.0) • Olevaprubart monotherapy Gender: Female 31%, Male 69% • No topical or systemic AD medications allowed Mean BMI (SD):
Slide 14: Olevaprubart proof of concept: notable, rapid improvement in AD skin signs among treated patients
Olevaprubart proof of concept: notable, rapid improvement in AD skin signs among treated patients in Phase 1b/2a Mean percent (%) change from baseline in EASI score Mean percent (%) change from baseline in BSA score Four-week oleva treatment with only three doses resulted in 87% mean reduction in EA
Slide 15: The majority of oleva-treated patients achieved 75% or more improvement in EASI score by week 16
The majority of oleva-treated patients achieved 75% or more and almost one third achieved 90% or more improvement in EASI score by week 16 Proportion of patients achieving EASI-75 and EASI-90 • EASI-75, a 75% improvement in EASI score or better, was achieved by 54%, 54% and 46% of participants at we
Slide 16: Early oleva data support favorable emerging safety profile; no fever or chills observed
Early oleva data support favorable emerging safety profile; no fever or chills observed Treatment-emergent adverse events in Phase 1b/2a Participants with at least one TEAE 9 (69%) • In the Phase 1b/2a of oleva in moderate-to- severe AD there were Study treatment related TEAEs 0 • No serious adverse
Slide 17: Th1, Th2, and Th17 biomarkers were reduced to within healthy volunteer ranges
Th1, Th2, and Th17 biomarkers were reduced to within healthy volunteer ranges in olevaprubart treated AD patients in the Phase 1b/2a proof-of-concept study Th1 serum proteins Th2 serum proteins Th17 serum proteins 50th percentile 50th percentile of healthy of healthy 50th percentile subjects subject
Slide 18: Robust Phase 2b study designed to inform Phase 3 dose selection
: Robust Phase 2b study designed to inform Phase 3 dose selection Study design varies loading regimen, dose, and dose interval and tests a wide range of olevaprubart exposures TRIPLE LOAD TREAT THROUGH DESIGN (Weeks 0, 1, 2) Q4W 600 mg Q4W 600 mg Q4W 300 mg Q4W 300 mg SCREENING 1:1:1:1:1 Q12W 600 mg
Slide 19: Oleva has shown proof-of-concept in alopecia areata
Oleva has shown proof-of-concept in alopecia areata • Alopecia areata (AA): Difficult-to-treat chronic a autoimmune disease characterized by hair loss People worldwide have • OX40 association: Upregulation of OX40 / OX40L in the lifetime ~2% risk of • Treatment options: JAK inhibitors are the only a
Slide 20: AA proof of concept: Oleva regrew hair with only 1 month (3 doses) of therapy
AA proof of concept: Oleva regrew hair with only 1 month (3 doses) of therapy Marked improvement over time, as measured by decline in SALT score Mean % change from baseline in SALT score Mean % change from baseline in SALT score by dose by baseline disease severity (600mg) • Hair regrowth without pl
Slide 21: Photographs of select AA patients after treatment with three oleva doses
Photographs of select AA patients after treatment with three oleva doses with marked hair regrowth Baseline Week 24 Baseline Week 16 Week 24 Week 36 Patient 1 Patient 3 Baseline Week 24 Patient 2 All three patients treated with 600mg doses at weeks 0, 2, and 4 21
Slide 22: Olevaprubart was well tolerated in AA PoC study; consistent emerging safety profile
Olevaprubart was well tolerated in AA PoC study; consistent emerging safety profile Oleva AA Phase 1b/2a patient demographics Oleva 300mg Oleva 600mg Oleva AA Phase 1b/2a treatment-emergent adverse Demographic/Baseline N=6 N=23 events occurring in two or more patients Ethnicity, n (%) White 5 (83%)
Slide 23: Imagene is well resourced with a clear path to value creation
Imagene is well resourced with a clear path to value creation IMG-007 designed with a trifecta of Build value: differentiating Topline data Focus on execution, drive IMG-007 (now oleva!) anticipated features Phase 2b in AD forward under amended protocol POC data in AD shows promising EASI from Phase
Slide 24: “amagene
RY “amagene